Focus on Neuroscience
Neurological and psychiatric disorders cause immense suffering and societal strain across the globe and their treatment remains a severe unmet need. Genentech is working to discover and develop transformative medicines for patients with major diseases of the nervous system. Presently we're focused on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as pain.
By using a multidisciplinary approach and a wide range of technologies, we seek to unravel the fundamental mechanisms underlying the biology and the diseases of the nervous system, and to translate these discoveries into innovative therapies for neurological disorders.
Science Translational Medicine, February 2015
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Science Translational Medicine, November 2014
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Nature, June 2014
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy
Journal of Experimental Medicine, October 2013
Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration
Nature, July 2012
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Journal of Neuroscience, July 2012
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ